Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viroflu + MVA-NP + M1
- Development stage
- Unknown
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
Viroflu + MVA-NP + M1 is a combination influenza vaccine regimen developed by the University of Oxford's Jenner Institute in collaboration with Vaccitech. It consists of the licensed seasonal virosome-adjuvanted vaccine Viroflu (also known as Inflexal V) and an investigational viral-vectored vaccine, MVA-NP+M1. The MVA-NP+M1 component utilizes a replication-deficient modified vaccinia virus Ankara (MVA) vector to deliver a fusion protein of two highly conserved internal influenza A antigens: nucleoprotein (NP) and matrix protein 1 (M1). While Viroflu provides standard protection by inducing antibodies against the surface hemagglutinin of seasonal H1N1, H3N2, and B strains, MVA-NP+M1 is designed to elicit potent T-cell responses that recognize conserved epitopes across different influenza A subtypes. This heterologous prime-boost-like co-administration strategy aims to provide broader and more durable protection than seasonal vaccines alone, potentially offering coverage against drifted or pandemic strains.
- Brand names
- Inflexal V
- Other names
- Viroflu + MVA-NP + M1-University of Oxford-influenzaMVA-NP+M1 + VirofluMVA-NP+M1 + Inflexal V
02
Targets
HA (Hemagglutinin)M1 (Muscarinic acetylcholine receptor M1)NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on Viroflu + MVA-NP + M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viroflu + MVA-NP + M1.